home / stock / tngx / tngx quote
Last: | $7.46 |
---|---|
Change Percent: | -2.74% |
Open: | $7.63 |
Close: | $7.67 |
High: | $7.63 |
Low: | $7.38 |
Volume: | 399,559 |
Last Trade Date Time: | 05/21/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$7.46 | $7.63 | $7.67 | $7.63 | $7.38 | 399,559 | 05-21-2024 |
$7.67 | $7.52 | $7.67 | $7.73 | $7.44 | 295,542 | 05-20-2024 |
$7.52 | $7.83 | $7.52 | $7.83 | $7.39 | 430,285 | 05-17-2024 |
$7.79 | $7.82 | $7.79 | $7.96 | $7.76 | 395,217 | 05-16-2024 |
$7.8 | $7.76 | $7.8 | $7.97 | $7.67 | 612,793 | 05-15-2024 |
$7.6 | $7.32 | $7.6 | $7.64 | $7.32 | 415,334 | 05-14-2024 |
$7.31 | $7.21 | $7.31 | $7.625 | $7.15 | 365,079 | 05-13-2024 |
$7.105 | $7.82 | $7.105 | $7.97 | $6.92 | 453,390 | 05-10-2024 |
$7.77 | $7.82 | $7.77 | $8.38 | $7.71 | 793,362 | 05-09-2024 |
$7.91 | $7.7 | $7.91 | $7.96 | $7.43 | 664,461 | 05-08-2024 |
$7.85 | $7.9 | $7.85 | $8.06 | $7.79 | 490,607 | 05-07-2024 |
$7.89 | $7.6 | $7.89 | $8.02 | $7.52 | 446,370 | 05-06-2024 |
$7.61 | $7.76 | $7.61 | $7.93 | $7.49 | 345,845 | 05-03-2024 |
$7.59 | $7.32 | $7.59 | $7.67 | $7.32 | 477,762 | 05-02-2024 |
$7.28 | $7.51 | $7.28 | $7.805 | $7.2 | 887,165 | 05-01-2024 |
$7.7 | $7.75 | $7.7 | $8.02 | $7.675 | 651,508 | 04-30-2024 |
$7.87 | $7.45 | $7.87 | $7.88 | $7.4 | 433,583 | 04-29-2024 |
$7.44 | $7.37 | $7.44 | $7.5 | $7.26 | 301,906 | 04-26-2024 |
$7.33 | $7.54 | $7.33 | $7.58 | $7.18 | 447,982 | 04-25-2024 |
$7.76 | $7.75 | $7.76 | $7.8 | $7.49 | 364,902 | 04-24-2024 |
News, Short Squeeze, Breakout and More Instantly...
Tango Therapeutics Inc. Company Name:
TNGX Stock Symbol:
NASDAQ Market:
– Dose expansion initiated in TNG908 phase 1/2 clinical trial – – Dose expansion expected to initiate in TNG462 phase 1/2 clinical trial in 2Q 2024 – – Clinical data expected in 2H 2024 from PRMT5 program – – Dose escalation...
– Dose escalation ongoing in four clinical-stage precision oncology programs; TNG908 phase 1/2 clinical data expected in 2024 – – First patient dosed in phase 1/2 clinical trial of TNG348 in patients with BRCA1/2-mutant and other HRD+ cancers – –...